Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Merit Medical Systems, Inc. (MMSI) Form 144 notice reports a proposed sale of 3,000 common shares valued at $265,683 to be sold through Morgan Stanley Smith Barney on NASDAQ on 08/22/2025. The filing states these shares were acquired the same day via stock option exercise and paid for in cash. The filer represents no undisclosed material adverse information about the issuer. The filing also lists a prior sale by Lynne Ward of 2,433 shares on 08/11/2025 for $206,535.91. Outstanding shares are listed as 59,219,117.
Lynne N. Ward, a director of Merit Medical Systems (MMSI), reported transactions dated 08/11/2025 on a Form 4. The filing shows the exercise of non-qualified stock options with an exercise price of $34.46 and an associated acquisition of 2,433 shares, and a contemporaneous sale of 2,433 shares at $84.8894.
Following the reported activity the form lists non-derivative beneficial ownership figures of 15,242 and 12,809 shares (as reported on separate lines) and indicates 3,000 derivative securities beneficially owned after the transactions, with 5,433 underlying common shares referenced for the options. The form is signed by an attorney-in-fact on 08/12/2025.
Merit Medical Systems (MMSI) submitted a Form 144 reporting a proposed sale of 2,433 common shares, with an aggregate market value of $206,535.91. The shares are listed on NASDAQ and the filing shows 59,219,117 shares outstanding for the issuer, indicating the position sold is a very small fraction of the company’s total shares. The securities were acquired and are being sold on 08/11/2025 as a result of a stock option exercise, and payment was in cash. The sale is to be executed through Morgan Stanley Smith Barney LLC, Executive Financial Services at 1 New York Plaza, New York.
The filing indicates Nothing to Report for securities sold in the past three months. The provided content does not identify the named seller or filer CIK in the visible text. The notice includes the standard attestation that the seller does not possess undisclosed material adverse information.